A Phase 2 Study to Determine the Pathological (path) Response to Neoadjuvant Nivolumab (nivo) and Relatlimab (rela) in Stage I to III Resectable Merkel Cell Carcinoma (Neo-Mcc).
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined